Tools
Upgrade to Pro 🌟

Upgrade for Pro stock ideas, Al signals, and more search.

Learn More

CSTL

Castle Biosciences, Inc. · NASDAQ

Performance

-3.98%

1W

+12.77%

1M

+24.17%

3M

+39.9%

6M

+54.26%

YTD

+85.36%

1Y

Profile

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Technical Analysis of CSTL 2024-11-08

The stock exhibits a strong bullish sentiment with a Moving Average Score of 96, indicating robust upward momentum, while the Technical Score of 73 further supports this positive outlook. However, the Oscillators Score of 50 suggests a neutral stance, indicating potential consolidation or indecision in the short term.
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of CSTL

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.